Suppr超能文献

DNA 回旋酶与喹诺酮类药物之间的相互作用:GyrA 亚基残基 Ser(83) 和 Asp(87) 处丙氨酸突变的影响。

Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).

作者信息

Barnard F M, Maxwell A

机构信息

Department of Biochemistry, University of Leicester, Leicester LE1 7RH, United Kingdom.

出版信息

Antimicrob Agents Chemother. 2001 Jul;45(7):1994-2000. doi: 10.1128/AAC.45.7.1994-2000.2001.

Abstract

DNA gyrase is a target of quinolone antibacterial agents, but the molecular details of the quinolone-gyrase interaction are not clear. Quinolone resistance mutations frequently occur at residues Ser(83) and Asp(87) of the gyrase A subunit, suggesting that these residues are involved in drug binding. Single and double alanine substitutions were created at these positions (Ala(83), Ala(87), and Ala(83) Ala(87)), and the mutant proteins were assessed for DNA supercoiling, DNA cleavage, and resistance to a number of quinolone drugs. The Ala(83) mutant was fully active in supercoiling, whereas the Ala(87) and the double mutant were 2.5- and 4- to 5-fold less active, respectively; this loss in activity may be partly due to an increased affinity of these mutant proteins for DNA. Supercoiling inhibition and cleavage assays revealed that the double mutant has a high level of resistance to certain quinolones while the mutants with single alanine substitutions show low-level resistance. Using a drug-binding assay we demonstrated that the double-mutant enzyme-DNA complex has a lower affinity for ciprofloxacin than the wild-type complex. Based on the pattern of resistance to a series of quinolones, an interaction between the C-8 group of the quinolone and the double-mutant gyrase in the region of residues 83 and 87 is proposed.

摘要

DNA 回旋酶是喹诺酮类抗菌药物的作用靶点,但喹诺酮与回旋酶相互作用的分子细节尚不清楚。喹诺酮耐药性突变经常发生在回旋酶 A 亚基的 Ser(83)和 Asp(87)残基处,这表明这些残基参与药物结合。在这些位置创建了单丙氨酸和双丙氨酸取代(Ala(83)、Ala(87)和 Ala(83) Ala(87)),并对突变蛋白进行了 DNA 超螺旋、DNA 切割以及对多种喹诺酮药物耐药性的评估。Ala(83)突变体在超螺旋方面完全有活性,而 Ala(87)突变体和双突变体的活性分别降低了 2.5 倍以及 4 至 5 倍;活性的这种损失可能部分归因于这些突变蛋白与 DNA 的亲和力增加。超螺旋抑制和切割试验表明,双突变体对某些喹诺酮具有高度耐药性,而单丙氨酸取代的突变体显示出低水平耐药性。通过药物结合试验,我们证明双突变酶 - DNA 复合物对环丙沙星的亲和力低于野生型复合物。基于对一系列喹诺酮的耐药模式,提出喹诺酮的 C - 8 基团与残基 83 和 87 区域的双突变回旋酶之间存在相互作用。

相似文献

1
Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87).
Antimicrob Agents Chemother. 2001 Jul;45(7):1994-2000. doi: 10.1128/AAC.45.7.1994-2000.2001.
2
Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
Am J Med. 1989 Nov 30;87(5A):2S-8S. doi: 10.1016/0002-9343(89)90010-7.
6
7
Effects of ciprofloxacin on plasmid DNA supercoiling of Escherichia coli topoisomerase I and gyrase mutants.
Antimicrob Agents Chemother. 1991 Jan;35(1):20-3. doi: 10.1128/AAC.35.1.20.
8
New Escherichia coli gyrA and gyrB mutations which have a graded effect on DNA supercoiling.
Mol Gen Genet. 1989 Oct;219(1-2):306-12. doi: 10.1007/BF00261192.
10
Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis.
J Antimicrob Chemother. 2001 Apr;47(4):447-50. doi: 10.1093/jac/47.4.447.

引用本文的文献

1
Developing a Gram-Negative Selective Peptide-Drug Conjugate.
ACS Omega. 2025 Aug 1;10(31):34151-34159. doi: 10.1021/acsomega.4c08000. eCollection 2025 Aug 12.
3
Antimicrobial peptide LL37 is potent against non-growing cells despite a slower action rate.
mSphere. 2025 Jan 28;10(1):e0021124. doi: 10.1128/msphere.00211-24. Epub 2024 Dec 23.
4
Interactions between Gepotidacin and Gyrase and Topoisomerase IV: Genetic and Biochemical Evidence for Well-Balanced Dual-Targeting.
ACS Infect Dis. 2024 Apr 12;10(4):1137-1151. doi: 10.1021/acsinfecdis.3c00346. Epub 2024 Mar 5.
6
Fluoroquinolone resistance does not facilitate phage Φ13 integration or excision in .
Access Microbiol. 2023 Jun 9;5(6). doi: 10.1099/acmi.0.000583.v4. eCollection 2023.
7
Current Worldwide Trends in Pediatric Antimicrobial Resistance.
Children (Basel). 2023 Feb 18;10(2):403. doi: 10.3390/children10020403.
8
DNA Gyrase as a Target for Quinolones.
Biomedicines. 2023 Jan 27;11(2):371. doi: 10.3390/biomedicines11020371.
10
and Activity of Gepotidacin against Drug-Resistant Mycobacterial Infections.
Antimicrob Agents Chemother. 2022 Dec 20;66(12):e0056422. doi: 10.1128/aac.00564-22. Epub 2022 Nov 29.

本文引用的文献

1
Compendium of DNA topoisomerase sequences.
Methods Mol Biol. 1999;94:279-316. doi: 10.1385/1-59259-259-7:279.
3
The interaction of drugs with DNA gyrase: a model for the molecular basis of quinolone action.
Nucleosides Nucleotides Nucleic Acids. 2000 Aug;19(8):1249-64. doi: 10.1080/15257770008033048.
4
Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates.
J Antimicrob Chemother. 1999 Dec;44(6):735-42. doi: 10.1093/jac/44.6.735.
7
Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance.
Antimicrob Agents Chemother. 1998 Nov;42(11):2978-84. doi: 10.1128/AAC.42.11.2978.
8
DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13991-6. doi: 10.1073/pnas.94.25.13991.
9
Crystal structure of the breakage-reunion domain of DNA gyrase.
Nature. 1997 Aug 28;388(6645):903-6. doi: 10.1038/42294.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验